HIV status defines distinct immunological drivers of persistent portal hypertension after HCV cure in people with advanced cirrhosis.

ABSTRACT:

Introduction

The immunological drivers of portal hypertension regression after hepatitis C virus (HCV) cure are poorly understood, particularly in the context of human immunodeficiency virus (HIV) coinfection We aimed to identify baseline immune signatures predicting the evolution of the hepatic venous pressure gradient (HVPG) in people with and without HIV (PWH/PWoH).

Methods

We prospectively followed 41 individuals with advanced cirrhosis (18 PWoH, 23 PWH) who were cured of HCV with direct-acting antivirals (DAA). Baseline plasma and cellular immune markers were extensively profiled using multiplex assays and flow cytometry. We used mixed-effects modeling to test for associations between these baseline immune features and the change in HVPG over a 48-week follow-up period,

SUBMITTER: Martin-Escolano R 

PROVIDER: S-EPMC12907311 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature